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Abstract: Breast cancer, as a heterogenous malign disease among the top five leading causes of cancer death worldwide, is defined as
by far the most common malignancy in women. It contributes to 25% of all cancer-associated deaths after menopause. Breast cancer
is categorized based on the expression levels of cell surface and intracellular steroid receptors [estrogen, progesterone receptors, and
human epidermal growth factor receptor (HER2)], and the treatment approaches frequently include antiestrogen, aromatase inhibitors,
and Herceptin. However, the management and prevention strategies due to adverse side effects stress the patients. The unsuccessful
treatments cause to raise the drug levels, leading to excessive toxic effects on healthy cells, and the development of multidrug-resistance
(MDR) in the tumor cells against chemotherapeutic agents. MDR initially causes the tumor cells to gain a metastatic character, and
subsequently, the patients do not respond adequately to treatment. Endoplasmic reticulum (ER) stress is one of the most important
mechanisms supporting MDR development. ER stress-mediated chemotherapeutic resistance is very common in aggressive tumors.
The in vitro and in vivo experiments on breast tumors indicate that ER stress-activated protein kinase R (PKR)-like endoplasmic
reticulum kinase (PERK)- activating transcription factor (ATF4) signal axis plays an important role in the survival of tumors and
metastasis. Besides, ER stress-associated oncogenic microRNAs (miRNAs) induce chemoresistance in breast tumors. We aimed to
have a look at the development of resistance mechanisms due to ER stress as well as the involvement of ER stress-associated miRNA
regulation following the chemotherapeutic regimen in the human breast tumors. We also aimed to draw attention to potential molecular
markers and therapeutic targets.
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1. Introduction
Amongst all the malignant diseases, breast cancer is one
of the leading causes of cancer mortality in the women
population worldwide, with 18.1 million new cases and 9.6
million cancer-related passing reported, according to the
2018 World Health Organization cancer case data. Breast
cancer rate differs widely, ranging from 27/106 (Africa and
Central-East Asia) to 85–94/106 (North America, Australia,
and Western Europe) (Sancho-Garnier and Colonna,
2019). Most breast cancers occuring the breast tissue
made up of hyperproliferation of the ducts that connect
the lobules to the nipple. After being constantly stimulated
by various carcinogenic risk factors, they are transforming
into localized tumors or even metastatic carcinomas
(Hosseini et al., 2019). Commonly therapeutic strategies
for sophisticated breast cancer patients with faraway organ
dissemination often are aforethought irremediable due to
negative results. As a heterogeneous disease, according to
molecular subtypes treatment approaches differ in breast
cancer. Molecular attributes comprise activation of HER22

(HER2, encoded by ERBB2), activation of hormone
receptors (estrogen receptor and progesterone receptor),
and/or BRCA mutations. Treatment of breast cancer is
multidisciplinary; it covers locoregional (surgery and
irradiation) as well as systemic treat attempts. Systemic
therapies contain anti-HER2 therapy for HER2-positive
disease, poly (ADP-ribose) polymerase inhibitors for
BRCA mutation carriers, the endocrinecure for hormone
receptor positive patients, chemotherapy, bone stabilizing
factors, and, nowadays immunotherapy (Harbeck et al.,
2019).
Resistance to chemotherapy, which is considered the
principal strategy in cancer treatment, constitutes serious
obstacles in terms of the treatment effect and the survival
process. It is thought that ability to adapt and rapidly
become resistant to chemotherapy occurs due to changes
in various biomarkers, with the inclusion of epigenetic
alterations, gene transmutation and/or amplification, and
miRNA expression. Taking into account tumor biology
it is necessary to the enlightenment of complex changes,
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the interactions of intracellular checkpoints, and the
underlying molecular mechanisms in a multidisciplinary
setting.In this way, therapy concepts will be following a
curative intent (Najjary et al., 2020).
Accumulating evidence indicates that one of
theremarkable mechanisms that support MDR
development is often mediated by the state of ER stress
as wellas the actuationof the unfolded protein response
pathways (UPR) within the intracellular endoplasmic
reticulum whichknown as the quality control center
of newly produced proteins. To maintain metabolic
homeostasis, UPR regulates the capacity to handle stress
and different pathways to block or encourage cell death.
Recently, molecular mechanisms linking ER stress and
durability to chemotherapy have been demonstrated in
isolated tumors, and the “multistress resistance” phenotype
hypothesis is advocated (Salaroglio et al., 2017).
Focusing on the mechanisms of resistance to
chemotherapeutic agents due to ER stress and miRNA
regulation in human breast tumors and alternative
potential therapeutic targets to the responsible molecular
markers has been amid in this review.
1.1. Multidrug resistance
Resistance to classical chemotherapeutics in cancer is
defined as a phenomenon in whichtumor cells become
tolerant of the pharmaceutical healer. As a form of
intrinsic cellular insensitivity, acquired resistance to
chemotherapeutic agents causes adverse impacts such
asmetastasis, chemotherapy unsuccess, and eventually
cancer-related death. Numerous mechanisms like
epigenetic alterations and/or genetic aberration also
various cellular and molecular mechanisms have been
proposed to mediate intrinsically or acquired MDR in
cancer cells (Wang et al., 2019; Mendes et al., 2020).
Important clinical studies aimedat identifying potential
MDR biomarkers, namely genetic variants, have been
conducted to predict sensitivity levels in drug-selected
model cancer cell lines (De Mattia et al., 2015; Zhang et
al., 2019). It is estimated that drug impact is immensely
mutable among patients and genetic variants comprise
20%–95% of the instability of drug-related response. The
results of investigations may help guide future research
and design individualized therapies in refractory cancer
and tumor recurrence (Mukerjee et al., 2018).
According to Li et al. (2017), the MDR contraption
is divided into seven sections. These are, respectively,
(i) increasing drug efflux by membrane transporters
as the primary transporters with ATP binding cassette
transporters (ABC), (ii) decreased drug intake by solute
carriers, (iii) blockage of apoptotic signaling through
mutations in the p53 pathway oralteration in the
expression level of B cell lymphoma (BCL) family proteins,
(iv) induced drug metabolism, including subtraction
bycytochrome P450 as well as glutathione S-transferase
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enzymes, (v) changing drug targets or hitting other
targets and signaling pathways, (vi) miRNA andepigenetic
regulation resulting in increased adaptation, and finally,
(vii) alterations in the microenvironment due to hypoxia
and cancer stem cell arrangement.
1.2. Innate and acquired drug resistance
1.2.1. Innate resistance
Natural resistance, which is generally described as
innate resistance, occurs before the patient is exposed to
medication and plays a vital role in drug efficiency. The
medicinal action of the administered drug can be lessened
by activation of the internal pathways that areused as a
cellulardefense. As the most common causes of innate
resistancein tumors; (i) preexisting genetic mutations that
result in a reduced ability of cancer cells to respond to both
chemo and target drugs, such as triple-negative breast
cancer cells; (ii) presence of insensitive subpopulations,
including cancer stem cells,developing adaptation with
drug therapy; (iii) internal pathways preferred as a defense
against ecological toxins (like anticancer remedy) (Huang
et al., 2016).
1.2.2. Acquired resistance
Acquired drug resistance could be depicted by the
fractional reduction of a drug’s anticancer activity after the
chemotherapy treatment.Acquired resistance may develop
due to (i) proto-oncogene activation; (ii) mutations or
varying expression grade of drug targets; (iii) alterations
in the tumor microenvironment (TME) after treatment.
When acquired drug resistance makes progress in
the tumor, to avoid a relapse in later stages of cure, the
treatment plan should be redesigned accordingly (Wang
et al., 2019).
1.3. Mechanisms of drug resistance
The importance of the molecular mechanisms of natural
and acquired resistance categories, as shown in Figure 1,
are examined is particularly important in terms of clinical
results and the determination of therapy strategies. The
clinical significance of the molecular contraptions of innate
and acquired resistance categories which can be obtained
over tumor progress and treatment is particularly crutial
in determining clinical results and therapy strategies
(Mendes et al., 2020).
1.3.1. Elevated efflux of drugs
Following drug intake into the cell, excretion of drugs
through carrier proteins localized in the cell membrane
has been accepted as the main cause of chemotherapy
resistance.The ATP-binding cassette (ABC) transporter
superfamily comprises transmembrane importers and
exporter proteins. A variety of substrates, including lipids,
sterols, metabolic products, and drugs, is translocating
by these carriers. Overexpression of ABC transporters is
often seen in tumors and multidrug-resistant cancer cells
(Vasiliou et al., 2008; Wilkens, 2015). The roles of ABCG2,
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Figure 1. Role of cells, protein factors, and mechanisms in drug-resistance
development in the tumor cell.

ABCB1, and ABCC1 proteins have been discussed in
several reports in MDR acquiring patients. ABCG2,
expressed on apical cell membranes, has a notable role in
tissue protection against various xenobiotics and carries
different endogenous and exogenous substrates, including
chemotherapeutic agents such as mitoxantrone and
various tyrosine kinase inhibitors, suggesting that ABCG2
is an important determinant of the pharmacokinetic
properties of drugs (Toyoda et al., 2019). Balaji et al.
(2016) have reported an increase in the mRNA levels of
ABCC1 and ABCC3 by exposing breast cancer cells to
doxorubicin (DOX), mitoxantrone (MXR), 5-flurouracil
(5-FU). Besides, the increased drug sensivity have been
exhibited in ABCC1 and ABCC3 knockdown model cell
lines (Balaji et al., 2016). The receptor tyrosine kinaselike orphan receptor 1 (ROR1), which is largely expressed
during embryogenesis but inhibited in normal adult tissue,
is the upstream regulator of ABCB1. Recent studies have
reported that ROR1 inhibition in breast tumors induces
chemosensitivity by modulating MAPK/ERK and p53
signaling pathways (Fultang et al., 2020).
1.3.2. Replacement of drug target
Conventional chemotherapy drugs slow down the
proliferation of tumor cells and encourage cell death.
Targeted therapeutic agents prevent cancer cell expansion
by targeting the activity of particular proteins effective in
tumor growth. At the same time, compared to traditional
chemotherapythey minimize the cytotoxic effects in
normal cells and therefore boost the success rate (Wang
et al., 2019). The new therapeutic strategies are focused

on multiple targets rather than a single one and inhibit
the activation of target changes mechanisms. However,
the crossinteractions of signaling pathways that affect the
performance of administered drugs cannot be ignored
(Cava et al., 2018). For example, in TNBC, AKT inhibitors
are deactivated by the activation of receptor tyrosine
kinases (RTKs) and therefore lose their effectiveness over
time (Duncan et al., 2012). Human EGFR 2 (HER2) and
epidermal growth factor receptor (EGFR) have a critical
impact in the initiation and progression of BC. The
inhibitors that target these receptor tyrosine kinases are
considered to be among the most successful targeted drugs
commonly used. The clinical and laboratory researches
have highlighted the role of the crosstalk between EGFR,
HER2 and other signaling pathways which is an important
molecular mechanism underlying chemoresistance
(Yamaguchi et al., 2014).
A recent computational in silico approach performed
by Cava et al. (2018) identified the altered signaling
pathways as prospective drug targets in BC subtypes. The
results of this study can be summarized as follows: (i) liver
X receptor-retinoid X receptor (LXR/RXR) activation
signaling, as a noval probable drug target specific for
luminal A; (ii) NAD biosynthesis II pathway, as main
potential drug target is exclusive in HER2 positive BC; and
finally (iii) aryl hydrocarbon receptor signaling pathway,
specific to basal like subtype (Cava et al., 2018).
1.3.3. Advanced DNA damage repair
The best part of chemotherapeutic agents such as cisplatin
and 5-fluorouracil (5-FU) activates cell death signaling
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pathways in tumorsby provoking DNA damage. The DNA
damage response (DDR) of cells touched by anticancer
agents by reducing the DNA repair mechanisms and
effectiveness of drugs, may lead to the progress of MDR
(Wang et al., 2019). Targeting DNA repair mechanisms
is considered as an important therapeutic approach in
breast tumors especially for those characterized by a
“BRCAness” phenotype including the “triple-negative”
subtype. BRCA1/2 has a significant effect on homologous
recombination (HR), which is the fundamental mechanism
in the repair of double-stranded DNA breaks (DSBs).
BRCA mutated breast cancer patients exhibit different
clinicandpathological characteristics related to indigenous
deficiency in HR DNA repair (Paluch-Shimon and Evron,
2019). The cisplatin-based neo-adjuvant clinical trials in
TNBC showed that homologous recombination deficiency
(HRD) is indispensable for cisplatin sensitivity. The
frequency of HRD is low in response to endocrine therapy
in HER2-overexpressing (HER2+) cell line (Manié et al.,
2015).
1.3.4. Senescence break
Senescence is a cellular process defined by the cessation
of cell division by age. It can be induced as a response to
stress conditions such as oncogenic activation, radiation,
genotoxic drugs, metabolic disruptions, DNA damage,
and encourage the prevention of irreversible malignant
cell growth. The lysine 9 trimethylation of p16INK4a, p21CIP1,
p53, and histone H3 (H3K9me3), which are known as
critical regulators of stem cell functions, have tremendous
effects on tumor aggressiveness and clinical treatment
success representing the basic signaling components of the
aging mechanism simultaneously (Milanovic et al., 2017).
Chemotherapeutic drugs are highlighted to affect many
cellular responses including activation of age-promoting
signals in the cancer cell and tumor microenvironment.
Therapy-related aging is a condition that can lead to the
disappearance of tumor cells by stimulating immune
surveillance and can be a source of chronic inflammation
and contribute to MDR development (Demaria et al.,
2016).
Experimental studies are showing that the treatment
of breast cancer patients with anthracycline and alkylating
agents causes p16INK4a dependent, telomere-independent
irreversible cellular aging, and the senescence-associated
secretory phenotype (Sanoff et al., 2014). The feature of
aging mechanisms thrivesamong different tumor cells. This
may partially elucidate the variability in chemoresistance
and treatment failure rates observed in clinical applications
(Demaria et al., 2016).
1.3.5. Epigenetic changes
Increasing evidence shows that epigenetic modifications
also participate in MDR mechanisms. Epigenetic
alterations are defined within the scope of DNA
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methylation, chromatin remodeling, histone modification,
and noncoding RNA-related mutations, which do not
involve sequence alterations in the DNA structurebut can
be transferred from cell to cell. Following chemotherapy,
tumor cells show a notable increase or decrease in the
expression levels of drug carriers (ABCB1, MDR), DNA
repair proteins, histone modifiers, or proapoptotic genes,
as a result of epigenetic changes (Assaraf et al., 2019).
Recent studiessuggest that chemoresistance is gradual,
multifactorial, and includes genetic and epigenetic
alterations. The mutations of epigeneticsmechanism
regulatory genes, including the ten eleven translocation
enzymes (TET), DNA (cytosine-5)-methyltransferase 3A
(DNMT3A) and polycomb repressive complex 2 (PRC2)
cause the disorganization of CSC pathways and managing
cellular reprogramming and finally can induce the acquired
chemo-resistance (Ponnusamy et al.,2019). In basal-like
breast cancer, a significant increase in bromodomaincontaining protein 4 (BRD4), lysine-specific demethylase
5B (KDM5B), and enhancer of zeste homolog 2 (EZH2)
activities was detected in tumor cell populations after
treatment with MEK and PI3K/mTOR inhibitors.
Moreover, it has been observed that the genes involved
in the SWI/SNF chromatin remodeling such as AT-rich
interactive domain-containing protein 1A ARID1A,
ARID1B and ARID2 are mutated in chemo-resistant
patients (Risom et al., 2018). According to preclinical
findings poor prognosis results with overexpression of
lysine demethylase 6B (KDM6B) and insulin-like growth
factor-binding protein 5 (IGFBP5) especially in luminal
subtypes is related to an epigenetic switch from H3K27me3
to H3K27Ac at the promoter region of GFBP5 gene (Wang
et al., 2018).
1.3.6. Tumor heterogeneity
Tumor heterogeneity is under review in four main
categories as genetic heterogeneity, cell type heterogeneity
(cancer cells, stromal cells, immune cells, etc.), metabolic
heterogeneity, and transient heterogeneity in dynamic
tumor progression. Uncontrolled changes in genetic,
epigenetic, and phenotypic modifications, including
microenvironment and metabolic imbalance, lead to breast
tumor formation. Breast tumors are characterized by cellto-cell, spatial and provisional heterogeneity features.
Sequencing analyzes prove that serious changes can occur
after neoadjuvant therapy and genomic modification.
However, it is a complicated situation, whether the observed
tumor changes externalize treatment-related clonal
evolution rather than preexisting intratumor heterogeneity
(ITH) (Baliu-Piqué et al., 2020). Whole exome sequencing
of primary breast tumors achieved by Caswell-Jin et al.
(2019) exhibited significant heterogeneity and large clonal
replacement and polyclonal resistance occurring in a small
tumor fraction. Finally, high resistance aberration rates
in these tumors were noted throughout treatment with
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chemotherapy and HER2-targeted therapy (Caswell-Jin et
al., 2019).
1.3.7. Tumor microenvironment
Tumors cannot be defined as homogeneous groups of
cancer cells. It encompasses a variety of cell types and
extracellular matrix (ECM) that cooperate with all aspects
of the cancer hallmarks.Immune cells, transformed ECM,
reprogrammed fibroblasts, soluble factors, signaling
molecules, immune suppressive cells and blood vessels
play substantial roles in the growth, inhibition of apoptosis,
angiogenesis, and drug resistance of solid tumors in a
coordinated manner within the tumor microenvironment
(TME). Exosomes as nanovesicles are promising in novel
treatment strategies by establishing the communication
scheme between TME and surrounding cells. The changes
caused by chemotherapy in TME have the potential to
induce the development of resistance and decrease in drug
efficacy by contributing to the adaptation of cancer cells
(Deepak et al., 2020). Upon the negative changes in the
microenvironment, tumor cells initiate the adaptation
process and activate various signaling cascades like mTOR,
NF-KB, AKT (Qu et al., 2019) .
Although tamoxifen is the most efficient in current
approaches for estrogen receptor α positive (ERα+) BC,
which make up the maximal proportion of BC patients,
development of resistance to tamoxifen in connection
with metastatic recurrence occurs in most patients during
the treatment. Gao et al. (2020) described the molecular
mechanisms underlying the contribution of TME in MDR
progress by designing a single-cell RNA sequencing in
Luminal A BC cells. Their finding has revealed a novel
subset of tumor-related fibroblast (CD63+ CAF) in theTME,
which downregulates ERα and PTEN expression in model
cell lines by means of exosomal miR-22, accordingly
provoke tamoxifen resistance (Gao et al., 2020).
1.3.8. Epithelial-mesenchymal transition
Mammary gland development, glandular regeneration,
normal morphogenesis and organogenesis have been
attributed to epithelial-mesenchymal transition (EMT)
programs. The activation of EMT in transformed breast
epithelial cells increases their ability to achieve invasive
and metastatic behavior, as well as the emergence
of chemotherapy-resistant breast cancer stem cells
(BCSCs) simultaneously (Gooding and Schiemann,
2020). Tamoxifen-resistant cells acquire mesenchymallike phenotypes mediated by upregulated expression
of mesenchymal markers (TWIST1, SNAIL, Vimentin,
N-cadherin,
fibronectin,
ZEB2),
downregulated
expression of epithelial markers (E-cadherin and miR27b). Besides, the increased activity of the glycogen
synthase kinase (GSK)-3beta and nuclear factor (NF)kappaB signaling in the regulation of Snail-mediated
E-cadherin also notable. The levels of methylation in the
miR-27b promoter region also takes place during EMT

(Kim et al., 2009; Li et al., 2016). Invasive breast cancer
subtypes acquire EMT phenotype after over activation
of the TWIST1/AKT signaling axis, leading to increased
migration, invasion, and resistance to paclitaxel (Cheng
et al., 2007). According to Gupta et al. (2009), EMT was
induced by silencing transformed telomerase activity and
shRNA-mediated E-cadherin expression in Ras mutant
HMLER breast cancer cells. As a result, they reported that
the population of CD44+/CD24− cell numbers increased
and these cells displayed mesenchymal cell formation,
tumor formation, and metastasis compared to epithelial
phenotypic cells, and most importantly, EMT supported
drug resistance mediated by CSC-like markers (Kong et
al., 2011). A recent study with the exposure to sublethal
doses of chemotherapy showed that the migration capacity
of BCSCs is uninfluenced while the sphere formation
potential of cells are increased and EMT-associated gene
expression at the mRNA level are altered significantly (Li
et al., 2020).
1.4. Signaling pathways associated with improvement of
multidrug resistance in breast cancer
Triple-negative breast cancer (TNBC) is the virulent
subtype of breast cancer due to its offensive nature and
deficiency of therapy options. Though optimal protocols for
TNBC therapy have not been established, chemotherapy
remains the onlysystemic treatment alternative. However,
it is observed that patients develop resistance to frequently
administered drugs. While anthracycline and taxanebased regimes are the basis for TNBC heal, platinumbased chemotherapies have exhibited controversial
results in the metastasis process. Consequently, immense
attempts have been done into clarifying the contraption
of TNBC chemoresistance, aimed to recognize novel
molecularobjects. Based on circumstantial interaction of
the TME, CSCs, drug efflux, and mass tumors the progress
of TNBC chemoresistance is sophisticated (Yuan et al.,
2016).
The stromal microenvironment of tumors includes
cancer stem cells (CSCs) and their heterogeneous progeny.
Transforming growth factor-beta (TGF-β) signaling as an
immunomodulator, without doubt, assists proliferation,
angiogenesis, EMT, metastatic distribution, and
chemoresistance. Epithelial and carcinoma cells undergo
a partial or complete epithelial-mesenchymal transition
(EMT) in response to transforming growth factor- β
(TGF-β). Katsuno et al. (2019) have been selected
HMLE, NMuMG and H-Ras-transformed carcinoma cell
populations to examine the molecular process of stem
cells, EMT phenotype, and drug resistance development,
related to time-dependent TGF- β exposure. Their results
have shown that short term (9–12 days) also long term (24
days) exposure induces reversible EMT and stable EMT,
respectively. While reversible EMT strongly increases the
emission and metastasis, the stabilized EMT phenotype
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cause to steady enhanced stem cell production which,
is accompanied by (mTORC1/mTORC2) signaling
pathways, resulting in anticancer drug resistance (Katsuno
et al., 2019).
TRIM32 with an E3 ubiquitin ligase activity, known
as the regulator of NF-κB signaling by ubiquitination of
protein inhibitor of activated STAT Y (Piasy). TRIM32
dysregulation has been implicated in various human
cancers. To examine the effect of TRIM32 on chemoresistance development of breast epithelialcells (MCF10A), and other ductal carcinoma, and invasive ductal
carcinoma cell lines, CCK8 assay and Western blot
analysis were employed. Their findings demonstrated
the decreasing TRIM32 expression in MCF-10A normal
breast epithelial cells. The overexpression of TRIM32,
upregulation ofIAPanti apoptotic protein, upregulation
of p-p65, p-IκB levels as NF-κB signaling activators and
downregulation of cell cycle inhibitors (p21 and p27) have
been resulted in cell viability and chemo-resistance in
MCF-7cells. Conversely, in T47D cells downregulation of
TRIM32, diminished cisplatin resistance and cell viability.
These data suggest that NFκB might be a potential target
for breast cancer initiation progress and chemoresistance
(Zhao et al., 2018). Abnormal JAK/STAT signaling
governs a series of processes such as survival, proliferation,
tumorigenesis, spreading, angiogenesis, immune
suppression as well as apoptosis. While IL6 and IL8,
which are among the genes identified to support TNBC
cell division, have a minor effect on estrogen receptor
positive tumor cells showed by in vitro and in vivo studies.
Conversely, simultaneous inhibition of IL6 and IL8 has
been reported to reduce proliferation, promote apoptosis,
and increase paclitaxel sensitivity (Hartman et al., 2013).
Dipeptidyl peptidase-4 (DPP-4) inhibitors are defined
as an oral hypoglycemic class that prevents inactivation
of glucagon-like peptide 1 (GLP-1) by blocking the
dipeptidyl peptidase-4 enzyme. In vivo and in vitro studies
showed the association between DPP-4 inhibition and the
increase of ABC transporters. Li et al. (2020) investigated
the effects of DPP-4 suppression on chemoresistance in
mouse and human breast cancer cell lines using specific
shRNA and DPP-4 inhibitor KR62436 in 4T1 cells. Their
findings suggest that there was no significant change
in the expression level of P-gp and ABCG2 in 4T1 cells
treated with the inhibitor. Whereas the levels of P-gp and
ABCG2 increased significantly in 4T1 cells treated with
doxorubicin (DOX) or the inhibitor and DOX combined
therapy. Finally, increased expression of ABC transporters
have been reported as a result of DPP-4 deficiency, and
that 4T1 cells acquired susceptibility to chemotherapyinduced apoptosis, mediated by the CXCR4/mTOR axis or
the TGF-β signaling pathway (Li et al., 2020).
Exosomes, subderivatives of extracellular vesicles
surrounded by a lipid bilayer membrane approximately
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100 nm in diameter, are considered to support the
development of tumor drug resistance. Lv et al. (2014)
used the ultracentrifugation method to form MCF-7/DOX
(doxorubicin-resistant) cells from drug-sensitive wildtype MCF-7 cells. By removing the exosomes from the cell
supernatant they have been accessed the P-gp expression
levels with flow cytometry. This study emphasizes that
P-gp transmission from exosome-mediated resistant
cells to parental drug-sensitive cells may be a significant
mechanism of drug resistance transfer. Growing evidence
connect the vital role of exosomes with angiogenesis,
migration, avoidance of immune cell attacks, metastatic
niche formation, MDR, and cancer progression. There
is an increasing interest in validating and incorporating
them into clinical applications in recent years (Osaki and
Okada, 2019).
In response to ATP treatment in breast cells, sex
determining region Y-box 9 (SOX9) is known as a chief
regulator of extracellular ATP signaling. In vitro invasion
and migration assays in a recent study demonstrated
that after ATP treatment in MDA-MB-231, BT-549, T47D,
and MCF10A breast cell lines, ATP-IL-6-SOX9 signaling
stimulate breast samples aggression and chemoresistance.
CEACAM5/6 defined as potential target genes of SOX9,
mediate ATP-induced invasion, and also ABCB1 and
ABCG2 to mediate ATP-driven chemoresistance.
According to the obtained results SOX9 could not be
ignored in novel treatment strategy approaches (Yang et
al., 2020).
The PI3K/Akt/mTOR pathway is highlighted as one
of the main causes of cancer cell resistance to antitumor
therapies. Dysregulation of this signaling pathway is
involved in a wide variety of cancer hallmarks enhancement
like proliferation, metabolic reprogramming, genomic
instability, immune response regulation, survival, and
motility. Despite the detailed clinical studies and the
presence of effective PI3K/Akt/mTOR inhibitors, the
underlying cellular events are not yet known, unfortunately
(Ortega et al., 2020).
Identification of MDR-related genes and pathways in
hormone receptor positive breast cancer cells performed
by KEGG analysis showed that target genes were supported
in several pathways, with the inclusion of tight junction,
calcium, CAM, or Wnt signaling pathways. Besides to
deterioration of homeostasis, interleukin-6, estrogen,
and nomegestrol acetate affect chemoresistance in breast
tumors (Yang et al., 2018).
With the three FDA approved selective CDK4/6
inhibitors: abemaciclib, palbociclib, and ribociclib, limited
success has been achieved as a result of intrinsic or acquired
resistance. One of the main factors of uncontrolled cell
proliferation and CDK4/6 inhibitor resistance frequently
seen in breast tumors is the deregulation of the cyclin
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D-CDK4/6-INK4-RB axis, upstream response, and
downstream bypass mechanisms (Li et al., 2020).
Numerous evidence has shown Exosomes’ main
role in BC advancement as intercellular communicative
vectors. Regulation of drug efflux and metabolism,
activation of bypass signaling or prosurvival pathways,
epithelial-mesenchymal transition, promotion of DNA
damage repair, stem-like characteristic, remodeling of
the microenvironment, and drug resistance (Dong et al.,
2020).
Recent work with O’Brien et al. (2020) in PIK3CA
mutant and wild-type ER+/HER2− cell lines revealed that
either a direct loss of Rb or loss of dependence on Rb
signaling confers cross-resistance to inhibitors of CDK4/6,
while PI3K/mTOR signaling remains activated. in the
absence of continued CDK4/6 inhibitor, Treatment with
the p110α-selective PI3K inhibitor, alpelisib (BYL719),
entirely blocked the progression of acquired CDK4/6
inhibitor-resistant xenografts (O’Brien et al., 2020).
1.5. Molecular mechanisms of the unfolded protein response
ER is defined as the site where newly produced proteins are
folded and subjected to posttranslational alterations before
being sent to the Golgi apparatus for their final integrity.
All proteins associated with the plasma membrane,

including ABC transporters, follow this process. Each
stage of protein modification agreeably folded proteins,
and unfolded/misfolded polypeptides, are continuously
inspected by the ER quality control system (ERAD/ERQC)
in the ER lumen (Jiang et al., 2020). UPR is crucial to
tailoring the ER folding capacity of cells under undesirable
conditions such as nutrient and oxygen deprivation.
PERK, ATF6, andinositol-requiring enzyme 1 (IRE1) are
three main sensors, first identified in mammals in the
late 1990s, to control the UPR process localized to the ER
membrane. Under normal conditions, these stress sensors
are kept ineffective owing to the ER chaperon, GRP78/BiP.
However, separating from GRP78/BiP transmembrane
proteins due to the developing stress, allowing them to
be activated (Figure 2). At this point, the aim is to induce
the expression of chaperones localized in the lumen and
to temporarily reduce protein synthesis. A triggered UPR
response offers the opportunity to restore ER capacity by
rebalancing the protein load and folding (Hotamisligil and
Davis, 2016).
Under normal conditions, the initial UPR signal begins
with the activationand homodimerization of IRE1, PERK,
and ATF6. IRE1α is the protein responsible for the initiation
of the UPR response by dissociating from BiP in the ER
lumen, is autophosphorylated, and induces the cut of the
6-basepair part of the XBP1 mRNA. Thus, the active XBP1

Figure 2. Activation of unfolded protein response downstream pathways
under ER stress condition.
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protein, a transcription factor, initiates the transcription
of ER lumen chaperones and inflammatory genes.
Autophosphorylation of IRE1α also provides activation of
jun N-terminal kinase (JNK), which is involved in stress
response. JNK is involved in the induction of caspase 12,
which is considered a biomarker in ER stress. PERK, the
second transmembrane protein involved in ER stress,
becomes autophosphorylated after BiP separation and
ensures that its subtarget, eukaryotic translation initiating
factor 2 α (eIF2α), is phosphorylated. With this inhibitory
phosphorylation of eIF2α, translation is suppressed and
the cell cycle stops. PERK also takes part in the activating
phosphorylation of ATF4 protein, which is a transcription
factor of CCAAT-enhancer-binding protein homologous
protein (CHOP). Finally, the activation of the ATF6
pathway is achieved by its translocation to the Golgi
cisternae and then to the nucleus. ATF6 is a transcription
factor that initiates the expression of genes encoding
enzymes disposed of for protein folding and ER-resident
chaperones (Hotamisligil and Davis, 2016; Hillary and Fitz
Gerald, 2018).
1.5.1. Multidrug resistance-associated with endoplasmic
reticulum stress in breast cancer
As shown in Figure 3, inconvenient peripheral
circumstances like hypoxic conditions, nutrient
deprivation, irradiation, and chemotherapy cause a series
of unfolded/misfolded proteins to collect in the ER lumen.
The elimination of unfolded polypeptides is driven by
ubiquitination, proteasomal/lysosomal degradation, or
autophagy systems (Li et al, 2020).

Along with the initiation, migration, differentiation,
metabolic changes, and adaptation processes to
environmental stresses in tumor cells a remarkable amount
of proteins are not properly folded. In these challenging
conditions, the adaptive arm of unfolded protein
response (UPR) capability and ER stress response (ERSR)
regulation is critical for cancer cell survival, depletion of
tumor suppressors, or activation of oncogenes and chemoresistance. (Avril et al., 2017). Recent studies emphasize
the critical role of UPR activation and chemotherapy
resistance in many subtypes of breast cancer (Table).
When it comes to chemoresistance, the role of UPR
in counteracting MDR is controversial. In different breast
tumor subtypes, UPR has been reported to support the
development of resistance to radiation therapy, paclitaxel,
tamoxifen, cisplatin, vinca alkaloids, doxorubicin,
microtubule-interfering therapeutic agents and histone
deacetylase (HDAC) inhibitors. On the other hand, UPR
has been observed to induce cell death in other treatment
approaches such as bortezomib, pan-peptidylarginine
deiminase lapatinib/obatoclax combination (McGrath
et al., 2018). In vitro and in vivo studies in this section
highlight the UPR role in cell fate via both promoting and/
or suppressing susceptibility to drug therapy and cell death.
Studies show that TM9SF4 knockdown in adriamycinresistant MCF-7 cells, which displays increased expression
in cancer patients with chemoresistant tumors, triggers
and increases ER stress level via upregulating ER stress
markers and initiating the subsequent apoptosis cascade
(Zhu et al., 2019). Vielanin K(VK) and doxorubicin (DOX)

Figure 3. Altered endoplasmic reticulum function can lead to multidrug
resistance.
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Table. Cellular models highlighting the importance of chemoresistance development in BC associated with ER stress and
UPR sensors.
Breast cancer
subtype
TNBC/
(mesenchymal stem
like, MSL)
TNBC/
(mesenchymal, M)
Normal epithelial
Normal epithelial
luminal A
HER2 positive
human and murine
TNBC cancer cells
Basal like TNBC
Luminal A
Basal like TNBC

Cell line

Therapeutic agent

Comments

Ref.

MDA-MB-231
BT-549
HBL-100

Betulinic acid (BA)
treatment

c-Myc-mediated glycolysis, apoptosis and
drug resistance occurrence as a result of
GRP78 Overexpression and PERK activation

Zheng et al.,
2019

MCF10A MCF7
SKBR3 T47D
MDA-MB-231
murine mammary
cancer JC cells
SUM-159PT
MDA-MB-436 MDAMB-468

Suppression of C/EBP-β LIP degradation
Doxorubicin treatment arises ER-dependent apoptosis, Pgp
downregulation, DC/CD8+T-lymphocytes
and lysosome/
proteasome inhibitors response reactivation and overcome
resistance to drug.
ATF4, CHOP pASK1 / JNK proapoptoticDocetaxel /NOSmediated ER stress response, caspases 3 /
inhibitor (L-NMMA)
9 cleavage promotion and withdrawal of
cotreatment
resistance.

MCF-7
MDA-MB-231

Taxol/Betulinic acid
cotreatment

Luminal A
HER2 positive
Normal epithelial
TNBC

MCF7 T47D SKBR3
MDA-MB-231 MDAMB-468 MCF10A

Tunicamycin (Tm),
MKC8866: selective
IRE1 RNase inhibitor,
Paclitaxel

HER2 positive
(ER+)

Rat DMBA-induced
mammary tumors

Isoflavone genistein
(GEN) during
tamoxifen (TAM)
therapy

Luminal A
(sensitive)
Luminal A
(resistant)

MCF-7
MCF-7/Dox

Nelfinavir (NFV),
doxorubicin (DOX)
cotreatment

Luminal A

T47D

Estrogen

MCF7-TAMR T47DTAMR

STF-083010 /
TAM cotreatment

MCF7/LCC1
(antiestrogen-sensitive
LCC1)
MCF7/LCC9
(antiestrogen-resistant
LCC9)

Selective ER
downregulator;
Fulvestrant (Faslodex;
ICI 182780; ICI)

Luminal A
(resistant)
Luminal A
(sensitive)
Luminal A
(resistant)

Enhancing chemo-sensitizing effects of taxol
via ER stress-mediated cell cycle arrest at
G2/M checkpoint induced by BA.
IL-6, IL-8, CXCL1, GM-CSF, TGFβ2
protumorigenic factors production through
IRE1 RNase activity. Increase efficacy of
chemotherapeutics with the support of the
IRE1 RNase suppression approach.
Lifetime GEN intake reduces de
novo resistance to TAM, compared with
postdiagnosis GEN groups. Either lifetime
or adult GEN intake inhibits TAM resistance
and reduces local mammary cancer
recurrence.
Increased UPR-transducers (Grp78, p-PERK,
p-eIF2α, and ATF4); and death sensors
(CHOP & TRIB-3). Increased AKT level is
linked to therapeutic resistance.
Overexpression of ER chaperones such as
BiP (GRP78 / HSAP5), p58IPK, calreticulin,
leads to survival, angiogenesis, and resistance
to chemotherapy.
Reduced sensitivity to TAM via XBP1s /
p-IRE1overexpression, STF-083010 Leading
to IRE1-XBP1regulation and restored tumor
sensitivity.
Inhibiting of antiestrogen-mediated
UPR activation and autophagy, as
critical resistance inducers. Overcoming
chemoresistance by means of ER-α
knockdown.

Salaroglio et
al., 2018
DávilaGonzález et
al., 2018
Cai et al.,
2018

Logue et al.,
2018

Zhang et al.,
2017

Chakravarty
et al., 2016
Andruska
et al., 2015
Ming et al.,
2015

Cook et al.,
2014

All figures were created by the authors using www.biorender.com.
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cotreatment in MCF-7/WT, MCF-7/MDR cells promotes
JNK protein phosphorylation and activates IRE1αTRAF2-JNK pathway, which in turn lead to mitochondrial
apoptosis and increased sensitivity to chemotherapeutic
drugs. Besides, IRE1α and JNK siRNA transfections
weakened combination treatment-induced apoptosis.
(Zhang et al., 2020). The effect of GRP78 expression as the
direct interacting target on drug resistance substantially
includes the reduced impact of drug-induced apoptosis.
In this respect Xie et al. (2016) showed that the ectopic
expression of GRP78 in MDA-MB-231 and MCF-7 wildtype and gemcitabine-resistant MDA-MB-231 and MCF7 tumors altered drug sensitivity. Recently, molecular
mechanisms linking ER stress and chemoresistance have
been elucidated in different tumors. Emerging evidence
suggests that cells that adapt to survive under severe ER
stress conditions simultaneously acquire resistance to
ER stress and chemotherapy. Gradual applications were
applied to tumor cells with dissimilar ER stress inducers
such as brefeldin A, tunicamycin, and thapsigargin. Cells
adapted to ER stress gain the MDR phenotype, boost PERK
expression, and PERK-linked Nrf2/MRP1 signal axis (Wu
et al., 2018). Drugs that provide acquired resistance to ER
stress can activate UPR-related genes such as P-gp, MRP1,
MRP2, MRP3, MRP5 (multidrug resistance-associated
proteins), and BCRP. Therefore, it is worth noting that
ER stress sensors can be MDR inducers (Salaroglio et
al., 2017). For instance, functional studies on TM9SF4
belonging to the transmembrane 9 protein (TM9SF)
family describe that TM9SF4 is effective in cell adhesion,
phagocytosis, and autophagy. Findings demonstrated that
shRNA-mediated TM9SF4 silencing increases ER stress by
causing misfolded protein accumulation in adriamycinresistant MCF-7 and gemcitabine-resistant MDA-MB-231
breast tumorscompared to wild-type cells and may result
in apoptotic and necrotic cell death activation.Based on
the findings, it emphasizes that TM9SF4 may be a possible
target therapy strategy to overcome the chemoresistance
barrier in breast cancer treatment (Zhu et al., 2019).
1.6. Oncomirs and multidrug resistance
MicroRNAs are transcribed from the intron or exon
regions encoding proteins on the genome and from DNA
sequences in regions that do not encode a protein. Indeed,
they are omnibus RNA molecules that do not translate
protein, only play a major role in normal biological
processes such as cell proliferation, differentiation,
and death (Shenouda and Alahari, 2009). Due to their
presence in blood circulation, their roles in many diseases,
especially cancer, have been investigated. Considering
the expression changes of miRNAs in tumor tissues and
the mRNAs they target, emerging evidence suggests that
these nonencoding proteins and small RNAs will provide a
significant opportunity in the early diagnosis of cancer and
the development of therapeutic agents. miRNAs, accepted
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as oncomirs when altered in tumor tissue, represent
different levels of expression in cancer cells.Accumulating
evidence support that various oncomirs play a vital role
in the immunopathogenesis of breast cancer as well
as in the development of chemoresistance, so they are
considered promising as valuable prognostic biomarkers
and therapeutical targets in distinct types of cancer
(Hemmatzadeh et al., 2019). Various miRNAs, especially
miR-122, miR-34c, let-7, miR-183, miR-200c, miR-203,
and miR-16 affect cancer pathobiology by focusing on
cellular and molecular targets important in breast tumor
development. It is known that they can induce genomic
instability by triggering DNA damage response. Besides,
as compared to normal stem cells,miRNAs have diverse
expression profiles in breast cancer stem cells, especially
miR-200b-200a, miR-200c-141 also miR-183-96-182 have
significantly lessened expression levels (Jafari et al., 2018).
1.6.1. Biogenesis and function of microRNAs
MicroRNAs (miRNAs), with approximately 22 nucleotides
in length, is a small set of noncoding RNAs that have a
prominent role in regulating gene expression.When
they bind to their complementary mRNAs, they induce
translational silencing or disruption of the target. miRNAs
are encoded by intergenic, intronic, or exonic regions
of other genes, as in Figure 4, and transcribed as a long
primary miRNA (pri-miRNA). It is processed into the
precursor miRNA (pre-miRNA) in the nucleus by the
Drosha enzyme. Afterward, they are exported to the
cytoplasm by Ran-GTP and Exportin-5, where they are
processed into mature microRNA (miRNA) with type III
RNAse, Dicer (Figure 4) (Shirjang et al., 2019).
1.7. Breast cancer and microRNAs
miRNAs generally target multiple mRNAs. According
to their expression or mutation levels, they can act as
apoptomirs (supporting apoptosis), oncomirs (tumor
promoters), or tumor suppressor miRNAs in different
cancers. Since 2005, when miRNA dysregulation was first
reported, there have been over 1000 studies identifying
and examining the role of miRNAs in breast cancer. Due
to the functional contribution of miRNAs in oncogenesis
and their effect on the formation of chemoresistance, it is
inevitable to consider them as molecular markers in the
progression of resistance mechanisms to achieve high
success in current chemotherapy applications (Shirjang et
al., 2019).
Oncomirs (e.g., miR-21, miR-221/222) can induce
cancer cell proliferation by reducing the expression of
tumor suppressor genes. Whereas tumor suppressor
miRNAs conversely target oncogenes. miRNA expressions
differ according to the defined clinicopathological
characteristics such as the stage of cancer, presence of
cancer-triggering mutations, administered drug, patient’s
survival process, and finally MDR. Mainly miR-34a, miR221, miR-222, miR-10a, miR-31, miR-106b and miR-93,
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Figure 4. Canonical miRNA biogenesis.

miR-29a, miR-30c, miR-125b, miR-21 are significantly
upregulated in breast tumors, lead to poor prognosis, and
are linked to drug resistance (Wu et al., 2014; Alamolhodaei
et al., 2017; Ke and Lou, 2017; Lv et al., 2017; Li et al., 2017;
Wu et al., 2019).
miR-21 has been shown as an indicator of clinical
diagnostic approaches due to its ability to target
proliferation signaling, tumor suppressor genes, metastasis
and MDR-associated oncogenic function in HER2+BC.
Overexpression of miR-21, advanced epithelialmesenchymal transition (EMT) has been demonstrated
in patients with poor prognosis (De Mattos-Arruda et al.,
2015; Najjary et al., 2020). The use of aromatase inhibitors
in postmenopausal HR+ patients are very common. miR
125b has been investigated among 90 patients of HR+
and metastatic BC to discover the molecular mechanisms
underlying MDR progress. The results showed that the
upregulation of AKT/mTOR pathway, overexpression
of miR-125b or the silencing of miR-424 expression
predispose the BC cells to acquire resistance to letrozole
and anastrozole compared to control group (Vilquin et
al., 2015; Zedain et al., 2020). The miRNA expressions
screening of 246 tamoxifen-treated BC patients results
indicated that miRNA-30c overexpression has a well
prognosis outcomes, by comparison to the group with
miRNA-30c low expression. The findings correlated the
overexpression of miRNA-30c with the motility signaling
pathways, and the stimulating growth factor receptor of
this pathway, PDGFRa, was linked as a possible cause of
tamoxifen resistance (Rodríguez-González et al., 2010;
Han et al., 2020). Hereby, as a result of extensive research
in this field, these small molecules are considered reliable

biomarkers in BC diagnosis and alternative therapeutic
approaches.
1.8. Regulation of endoplasmic reticulum stress-activated apoptosis by microRNAs
Posttranscriptional control, downstream of UPR, is one of
the main important mechanisms in cancer development.
This phenomenon is achieved through the selected mRNA
expressions directly or transcriptional regulators such as
miRNAs (Chevet et al., 2015). For example, miR-23a, miR27a, miR-24-2 stimulates the expression of components
such as CHOP, TRIB3, ATF3, and ATF4 in HEK293T
cells, resulting in ER stress-induced apoptosis (Chhabra et
al., 2011). To maintain tissue and organism homeostasis,
damaged cells are abolished through programmed cell
death, apoptosis, accompanied by miRNA surveillance.
miRNAs are defined as apoptomir or oncomir in
distinct tumors. While oncomirs support tumor growth,
apoptomirs have been shown to control apoptotic pathways
by targeting Bcl-2, Mcl-1, TRAIL, Fas, and p53 mRNAs
(Shirjang et al., 2019). UPR’s three main receptors stimulate
proapoptotic agents by performing CHOP activation,
which is important for determining cell fate. It can urge
apoptosis by targeting genes like GADD34 (growth arrest
and DNA-damage-inducible 34), TRIB3, Bax, and Bcl-2.
For example, the adapter protein, Src homology 2 domain
containing 1 (SHC1), and the proapoptotic protein Bax are
affected directly by overexpressed miR-365 leading to the
occurrence of gemcitabine resistance in PDAC patients in
invasive pancreatic ductal adenocarcinoma cells (PDAC).
miR-125b provides resistance of breast cancer cells to
paclitaxel by suppressing proapoptotic Bak expression.
miR-491, by targeting Bcl-xL, has a role in inducing
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apoptosis, and significantly reduces the survival of human
DLD-1 colorectal tumors. Also, miR-24-2c andmiR-148a
reduce Bcl-2 expression. Moreover, miR-27a/b, miR-23a/b
can control the sensitivity of neurons to apoptosis, as they
act as endogenous inhibitors of APAF-1 expression. It has
been reported that miR-24a and miR-133 directly inhibit
caspase-9 to determine cell destiny. miR-211 induced by
ER stress facilitates histone H3K27 methylation, resulting
in the inductionof CHOP expression and cell survival. The
expression level of miR-708 is enhanced by CHOP, which
plays a major role in controlling ER stress and maintaining
ER homeostasis (Figure 5) (Su et al., 2015).
2. Conclusion
Many chemical drugs preferred in clinical applications in
cancer treatment, unfortunately, have a huge prevalence of
traumatic side effects and MDR. Moreover, the existence
of tumors at risk of becoming resistant to chemotherapy
remains a serious obstacle to the chance of success in the
treatment of various types of cancer. Indeed, many studies
are being conducted on probable candidate therapeutic
agents that have the potential to trigger other pathways to
obtain alternative MDR modulators. The gene expression
profile of cancer cells is a valuable tool in identifying new
clinical biomarkers and molecular pathways underlying
disease. Therefore, extensive research is needed to elucidate

molecular mechanisms to develop effective targeted
therapy options. The conflicting findings regarding the
role of UPR, which is activated in cancer cells causing
drug resistance, emphasize the need to understand the
specific nature of UPR. Since the duration of ER stress is
a determinant of cell fate, it iscritical to know how much
the therapeutic dose obtained in tumor cells triggers ER
stress.The fact that independent of the mechanism of
action of drugs, ER stress, and UPR support cell survival
or death should be considered as a determining factor.In
conclusion, since UPR signaling mechanisms are active
in breast cancer, it should be followed closely during the
treatment processes of especially aggressive breast cancer
patients in the clinic, because of its potential to promote
the development and progression of the disease and to
contribute to therapy resistance. Overall miRNAs act as
modulators or effectors against UPR-associated sensors
triggered by the ER stress, also the control of protein
translation and ER entry, multidrug resistance development.
However, by regulating target mRNAs in the progression
of tumors, miRNAs show a suppressive and/or stimulating
impact on gene expression and activation of prominent
pathways. Studies have observed remarkable changes in
the miRNA expression profile of resistant types in contrast
to drug-sensitive cells. Up-to-date data obtained from the
empirical studies mentioned in this review proves that

Figure 5. miRNA regulation of apoptosis and ER stress signaling pathways.
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master miRNAs target multiple basic signaling networks,
tyrosine kinase receptor pathways, epigenetic suppressors,
and transcription factors in tumors. It is also nominated as
an MDR regulator by abnormally modulating the levels of
various important gene expression modulators. Functional
miRNAs as important candidate diagnosis and prognostic
indicators of breast cancer are used in the development of

new and more effective individualized therapies for cancer
treatment. Hence the data obtained from the miRNA
profile analysis of patients offer new opportunities for
safer and faster diagnosis and planning heal processes.
Numerous new techniques such as gene sequencing,
proteomics, and microRNA analysis have been proposed
to enhancement the survival procedure in cancer therapy.
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